Short answer
Schrodinger, Inc. (SDGR) filed an 8-K current report with the SEC on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Third-quarter financial results for period ended September 30, 2026 announced.
Schrodinger, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Third-quarter financial results for period ended September 30, 2026 announced
- Investors should review Exhibit 99.1 for revenue, profitability, guidance and segment performance details
- Results announcement provides the latest operating update for Schrödinger’s software and drug-discovery businesses
Item 7.01 · Regulation FD Disclosure
- Company corrected ASH abstract: SGR-1505 combination study in relapsed/refractory B-cell malignancies has not started
- SGR-1505 development depends on identifying strategic partnership opportunities
- Correction signals potential development delay and increased uncertainty for the MALT1 inhibitor program
- Phase 1 data remain the underlying disclosure, but investors should rely on corrected study-status information
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $64.5M, up 19%, led by drug discovery revenue of $24.2M versus $13.0M
- ACV $44.7M, up 17%, with hosted software revenue up 49% to $17.2M
- Raised 2026 ACV guidance to $222M-$232M and drug discovery revenue guidance to $75M-$85M
- Net loss widened to $37.7M from $32.8M, primarily reflecting $11.4M of other expense from equity-market value changes
- Tectora contributed two early-stage programs for equity, milestones and royalties, expanding potential pipeline participation without stated upfront cash proceeds
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Schrodinger, Inc. 8-K filings
Get the next SDGR 8-K as it lands
Follow SDGR for push alerts, or ask the research agent what this filing means.